Larson has authored or coauthored 430 manuscripts in major peer-reviewed journals, including *Science*, *Nature Medicine*, *Nature Biotechnology*, *Radiology*, the *New England Journal of Medicine*, and *The Journal of Nuclear Medicine*. He has also served on several governmental advisory committees and study sections at the NIH, the DOE, and FDA. He currently serves on the Biologic, Environmental Research Advisory Committee (BERAC) of the DOE and the Advisory Committee of the Department of Life Sciences for Brookhaven National Laboratory.

“I am deeply honored by this awesome recognition and to be identified with the giants in nuclear medicine who have received this award before me,” said Larson, who expressed his appreciation to friends, colleagues, collaborators, and family members. “The current nuclear medicine trainees at MSKCC, both residents and fellows, provide enthusiasm and energy that continuously regenerate a creative clinical and research environment. I have no doubt that one day, some of these fine scientists will make their indelible marks on our field.”

Aebersold Award Presented to Goldenberg

David M. Goldenberg, ScD, MD, founder and president of the Garden State Cancer Center and the Center for Molecular Medicine and Immunology (Belleville, NJ), received the 2005 Paul C. Aebersold Award for outstanding achievement in basic science applied to nuclear medicine on June 19 at the 52nd Annual Meeting of the SNM, held in Toronto, Canada.

The Aebersold Award is named for Paul C. Aebersold, a pioneer in the biologic and medical application of radioactive materials and the first director of the Atomic Energy Commission’s Division of Isotope Development at Oak Ridge, Tenn. The first Aebersold Award was given by SNM in 1973. “I am humbled to be among these giants of nuclear medicine,” said Goldenberg. “I am especially grateful to the society for recognizing me, a nonnuclear physician, for my contributions to basic science applied to nuclear medicine. Science often takes us down unpredictable paths, and I certainly did not plan to conduct nuclear medicine research when I embarked on cancer biology, pathology, immunology, and genetics.”

Goldenberg pioneered the development of radiolabeled antibodies for various applications in the detection, diagnosis, and therapy of cancer. Under his leadership, scientists and clinicians at the Garden State Cancer Center have developed antibodies for the diagnosis, detection, and treatment of solid tumors such as colorectal, pancreatic, lung, breast, and ovarian cancers, as well as hematologic cancers such as lymphoma and multiple myeloma. He has overseen the in-house clinic as well as clinical outreach at affiliated institutions in the United States and Europe for treatment of cancer patients with radiolabeled antibodies. He also helped develop 2 diagnostic radiopharmaceuticals marketed by Immunomedics Inc., which he established in 1982. He is also the president and chief executive officer of CMMI, a not-for-profit, independent, specialized research center that focuses on the development of biological strategies to detect and treat cancer and immunological diseases.

Over the past 30 years, Goldenberg has been a major contributor to knowledge of the basic principles of the preparation and utilization of radioimmunoconjugates in medical diagnosis, including functional imaging and guided radionuclide therapy. He has published more than 500 articles in peer-reviewed journals and is currently exploring the use of PET tracers in immunodiagnosis and therapy, especially by pretargeting methods he and his colleagues are developing, and the use of new humanized antibodies for the treatment of lymphomas and autoimmune diseases. He has edited 2 books on radiolabeled antibodies and 10 journal supplements to *Cancer*, *Cancer Research*, and *Clinical Cancer Research*.

He has received numerous professional awards and recognition by scientific bodies, including McGill University, the Indian Society of Nuclear Medicine (Sarabhai Memorial Oration), the Swedish Oncology and Radiology Societies (Elis Bervin Lecture/Medal), the International...
Goldenberg received an SB degree from the University of Chicago in 1958, an ScD from the Faculty of Natural Sciences of the University of Erlangen–Nuremberg in 1965, and his MD from the University of Heidelberg’s School of Medicine in 1966. He has faculty appointments in pathology at the University of Pittsburgh, Temple University, and the University of Kentucky and adjunct professorships in medicine, surgery, and microbiology/immunology at the University of Medicine and Dentistry of New Jersey and New York Medical College. He is currently an editorial board member of several journals, including The Journal of Nuclear Medicine, the International Journal of Tumor Markers, the Quarterly Journal of Nuclear Medicine and Molecular Imaging, Current Medical Imaging Reviews, Current Cancer Therapy Reviews, and Cancer Biotherapy and Radiopharmaceuticals. He has also served as chair of the merit review board in oncology for the Veterans Administration and a member of the Experimental Immunology Study Section of NIH.

Robertson Receives Loevinger–Berman Award

At a ceremony on June 19 preceding the second session of the Medical Internal Radiation Dose (MIRD) Committee Continuing Medical Education course on Advances in Patient-Specific Dosimetry at the SNM Annual Meeting in Toronto, Canada, Stephen R. Thomas, PhD, vice chair of the MIRD Committee, presented James S. Robertson, MD, PhD, with the 2005 Loevinger–Berman Award for Excellence in Internal Dosimetry.

The award was established in 1999 in honor of Robert Loevinger and Mones Berman, who formulated the MIRD schema for internal dose calculations. The award is given in recognition of excellence pertaining to the field of internal dosimetry as it relates to nuclear medicine through research and/or development, significant publication contributions, or advancement of the understanding of internal dosimetry in relationship to risk and therapeutic efficacy. Previous award winners have included Roger J. Cloutier (1999), Dandamudi V. Rao (2000), Keith F. Eckerman (2001), Sven-Erik Strand (2002), John W. Posston, Sr. (2003), and Roger W. Howell (2004).

Robertson received his medical degree from the University of Minnesota (Minneapolis) in 1945, followed by an internship at the U.S. Naval Hospital (Annapolis, MD). He received a doctorate from the University of California at Berkeley in 1949 after completing a thesis entitled “Lung Ventilation Patterns and Their Physiological Significance.” He then moved to the Brookhaven National Laboratory (Upton, NY), where he remained for 25 years, from 1950 to 1975. During this time he was engaged in a spectrum of nuclear medicine–related activities that included PET, neutron capture theory, radiation dosimetry, compartmental analysis, analog computers in kinetic analysis, medical computer applications, and whole-body gamma spectrometry. Much of this work was truly avant-garde for the period, as PET technology was just being introduced along with the applications of computers and data analysis in medical imaging. Of particular importance were Robertson’s investigations in the area of compartmental models and kinetic analysis. Many of his contributions to the field of dosimetry were associated with these topics.

From 1975 until 1985, Dr. Robertson was a member of the Department of Nuclear Medicine at the Mayo Clinic (Rochester, MN), where, along with his clinical
Aebersold Award Presented to Goldenberg


This article and updated information are available at:
http://jnm.snmjournals.org/content/46/9/24N.citation

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml